Background Prospective, population-based study of an 8-year follow up. To determine the
direct cost of diabetic retinopathy [DR], evaluating our screening programme and the cost of …

Objective Anti–vascular endothelial growth factor therapies have revolutionized the
treatment of clinically significant diabetic macular edema (CSDME); yet these agents are …

Purpose To examine the comorbidity profile and update estimates of health care resource
utilization for commercially insured, working-age adults with diabetic macular edema (DME) …

OBJECTIVE To simulate economic outcomes for individuals with diabetic macular edema
(DME) and estimate the economic value of direct and indirect benefits associated with DME …

OBJECTIVE To evaluate changes in the incidence, prevalence, severity, and onset age of
visual impairment (VI) due to diabetic retinopathy (DR) and compare these trends in the …

Purpose: To assess the direct medical expenditures associated with Diabetic Macular
Edema (DME) and Diabetic Macular Edema with Visual Impairment (DME/VI) from a US …

Purpose To characterize the natural course of diabetic retinopathy (DR) in contemporary
clinical practice. Patients and Methods This was a retrospective analysis of US claims data …

Objective: This retrospective cohort study examined the impact of diabetic macular edema
(DME), diabetic retinopathy (DR), or diabetes on annual health benefit costs and …

BACKGROUND AND OBJECTIVE: To describe the frequency and variation of intravitreal
bevacizumab (Avastin; Genentech, South San Francisco, CA) and ranibizumab (Lucentis; …

Purpose Intravitreal anti-vascular endothelial growth factor (VEGF) pharmacotherapy has
become standard of care for the management of diabetic macular edema (DME). The …